SOHO 2022 | Using MRD and mutational analysis when selecting patients with T-ALL for transplantation
Josep-Maria Ribera, MD, PhD, University of Barcelona, Barcelona, Spain, explains which T-cell acute lymphoblastic leukemia (T-ALL) patient subgroups should be considered for allogeneic transplantation, including those who are measurable residual disease (MRD) positive after induction or consolidation therapy and those with early T-cell precursor (ETP) T-ALL. Prof. Ribera also comments on key mutations which influence indication for transplantation, such as RAS and absence of NOTCH-1. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
